Ciena [CIEN]
Task 6 | Built 2026-07-27 | migrated to the Criteria framework 2026-07-29 | framework v1.5.1
NO POSITION VERDICT. The prior header read Position: SHORT 1.0% (staged); that verdict is deleted. The
columns below previously read "Downgrade (evidence for impairment)" and "Upgrade (evidence against impairment)" — they are now simply the
two directions in which each event moves the evidence. Nothing here instructs a trade.
Every entry carries an explicit upgrade/downgrade threshold. Ongoing maintenance hands off to equity-research:catalyst-calendar and equity-research:thesis-tracker.
| Date | Event | Status | What it tests | Evidence FOR impairment | Evidence AGAINST impairment |
|---|---|---|---|---|---|
| 2026-09-03 (before open) | FQ3-26 results + call | Confirmed | Whether backlog keeps rising while binding coverage keeps falling | Backlog quoted higher again without a proportional RPO rise; any further retreat from quantified disclosure | Backlog quantified with coverage context; book-to-bill reinstated |
| ~2026-09-05 (within days of results) | FQ3-26 10-Q filed — MANDATORY ASC 606 RPO DISCLOSURE | Statutory | THE thesis test. The single audited number in dispute | RPO ≤ $2.8bn (coverage <33% on a ~$8.5bn backlog) → the mechanism is confirmed on audited data | RPO ≥ $3.4bn (coverage ≥40%) → the mechanism is refuted on audited data |
| ~2026-12-10 | FQ4-26 / FY2026 results + FY2027 GUIDANCE | Estimated (FY25 analogue: 2025-12-11) | The Consensus Criteria variant itself | FY2027 revenue guide < $7.8bn → thesis confirmed, hold to target | FY2027 guide ≥ $8.5bn with RPO > $3.5bn → close |
| ~2026-12-12 | FY2026 10-K filed | Statutory (FY25 analogue: 2025-12-12) | Whether the Item 1 backlog section returns | Backlog section still absent, or present without a >1yr split | Full section reinstated with coverage >55% |
| Date | Event | Relevance | Threshold |
|---|---|---|---|
| Late Oct 2026 | Big-four hyperscaler Q3 CY2026 results and 2027 capex framing (MSFT, GOOGL, AMZN, META) | The demand leg of both cases | Aggregate 2027 capex signalled >$1.0trn → bear case weakens materially, reduce size. Any hyperscaler guiding to a digestion year → add |
| ~Nov 2026 | Coherent (COHR), Lumentum (LITE), Fabrinet (FN) prints | Supply-chain read-through; correlations 0.67–0.71 | Component book-to-bill falling below 1.0, or lead times shortening → order inflation unwinding → add |
| Mar 2027 | OFC 2027 | Hyper-Rail commercialisation vs. demo | Named customers and quantified multi-rail deployments → bull leg strengthens |
| Ongoing, bi-monthly | Short-interest updates | Crowding | SI >8% of float → reassess squeeze risk |
| Any time | 8-K disclosing a large multi-year non-cancelable award | Would directly repair the coverage ratio | A single contract >$1.5bn non-cancelable → reduce |
| From 2026-09-15 | Convertible hedge/warrant flows | Technical | Immaterial at $377 vs a $746.66 conversion price |
backlog, RPO, book-to-bill, cancel*, lead time, pricing against the pinned 16-quarter Alpha Vantage baseline.FQ3-26 10-Q RPO
├─ ≤ $2.8bn (coverage <33%) → CONFIRMED. Add to full 1.0%. Hold to Dec guidance.
├─ $2.8–3.4bn (33-40%) → INCONCLUSIVE. Hold starter 0.5%. Re-underwrite at Dec.
└─ ≥ $3.4bn (≥40%) → INVALIDATED. Close. Log to CALIBRATION_WATCH.md.